Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has issued 1,736,111 fully paid ordinary shares to CVI Investment Inc. following the conversion of five zero coupon convertible notes, expanding its share capital under ASX code IMU. The company confirmed the issuance was conducted without a prospectus under the Corporations Act disclosure exemptions, while affirming ongoing compliance with its financial reporting and continuous disclosure obligations and stating that no excluded information is being withheld from the market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited (ASX: IMU) is a clinical-stage immuno-oncology company developing novel immunotherapies designed to activate the immune system to treat and eradicate cancerous tumours. Its pipeline includes the off-the-shelf allogeneic CAR T cell therapy azer-cel (azercabtagene zapreleucel) targeting CD19-positive blood cancers, as well as CF33 oncolytic virotherapy candidates aimed at a range of solid tumours, often in combination with standard-of-care treatments and emerging immunotherapies.
Average Trading Volume: 1,397,104
Technical Sentiment Signal: Sell
Current Market Cap: A$109.7M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.